New Phase IV Clinical Study Indicates LidoSite Provides Rheumatology Patients Superior Pain Relief
FAIR LAWN, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN), today announced results from a new phase IV "Open Label" clinical study demonstrating that LidoSite, the first FDA approved active patch for dermal analgesia, provided better pain relief to more than 73 ...Vyteris - LidoSite, The first FDA-approved active patch
Home > Our Products > LidoSite ... Nurses also appreciate how LidoSite is extremely easy to administer. ... The LidoSite system is contraindicated in patients ...Vyteris - The Future of Drug Delivery
Smart Patch Drug Delivery. Vyteris' ... LidoSite® Our first product, LidoSite, which provides dermal analgesia prior to ... Learn more about LidoSite. News ...LidoSite information from Drugs.com
LidoSite is a local anaesthetic that numbs the skin. ... LidoSite uses an active transdermal delivery technology known as iontophoresis, ...New Localized Pain Treatment System Available From B. Braun
... announced today the availability of the LidoSite Topical System, a method t ... "LidoSite proves that lidocaine iontophoresis provides not only faster, ...Summary of VYTERIS HOLDINGS (NEVADA), INC. - Yahoo! Finance
LidoSite is a topical delivery system indicated for use on normal intact skin to ... Our LidoSite product uses our technology to achieve rapid, deep local anesthesia ...